Is Reluctance to Share Alzheimer’s Disease Biomarker Status with a Study Partner a Barrier to Preclinical Trial Recruitment? | Zendy

Chelsea G. Cox | Zendy; Mary Ryan | Zendy; Daniel L. Gillen | Zendy; Joshua D. Grill | Zendy

Open Access

Is Reluctance to Share Alzheimer’s Disease Biomarker Status with a Study Partner a Barrier to Preclinical Trial Recruitment?

Author(s) -

Chelsea G. Cox,

Mary Ryan,

Daniel L. Gillen,

Joshua D. Grill

Publication year - 2020

Publication title -

the journal of prevention of alzheimer s disease

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.733

H-Index - 13

eISSN - 2426-0266

pISSN - 2274-5807

DOI - 10.14283/jpad.2020.36

Subject(s) - biomarker , logistic regression , confounding , medicine , clinical trial , test (biology) , informed consent , psychology , odds ratio , clinical psychology , alternative medicine , pathology , biology , paleontology , biochemistry , chemistry

Preclinical Alzheimer's disease clinical trials test candidate treatments in individuals with biomarker evidence but no cognitive impairment. Participants are required to co-enroll with a knowledgeable study partner, to whom biomarker information is disclosed.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research